CN1087277A - Contain slow releasing composition of growth hormone and preparation method thereof - Google Patents
Contain slow releasing composition of growth hormone and preparation method thereof Download PDFInfo
- Publication number
- CN1087277A CN1087277A CN93101680A CN93101680A CN1087277A CN 1087277 A CN1087277 A CN 1087277A CN 93101680 A CN93101680 A CN 93101680A CN 93101680 A CN93101680 A CN 93101680A CN 1087277 A CN1087277 A CN 1087277A
- Authority
- CN
- China
- Prior art keywords
- growth hormone
- tocopherol
- composition
- slow releasing
- freezing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of somatotropin composition of slow release, long half time and having no side effect in animal body, also relate to its method for making, comprise that mixed growth hormone and lecithin makes a mixture, this mixture of dissolving is made a kind of liposome growth hormone solution in aqueous solution, freezing this solution, this liposome growth hormone after freezing that suspends in Tocopheryl derivatives is made above-mentioned slow releasing composition.
Description
The present invention relates to a kind of growth hormone slow release (release-controlled) compositions that contains, it is long half time in animal body, does not have the usefulness of paying, and the invention still further relates to a kind of method for preparing said composition.
The growth hormone formulations of most biologically active all has the short relatively half-life in vivo.For sufficiently high biological agent being provided and keeping the biological activity of growth hormone to prolong, have in a large number and/or often supply medicine, may cause the damage serious like this to the administration animal.Therefore, in case supply with growth hormone in vivo, promptly need one to prolong its effect and the therapeutic regimen harmless again to animal.In order to address that need, to have developed various productions and had the interest for delinquency release characteristics and reduce administration frequency or the method for the somatotropin composition of dosage.
For example, United States Patent (USP) 4,985,440 disclose a kind of a kind of transition metal composite that contains, the compositions of particularly a kind of zinc one growth hormone complex, said composition is dissolved in vegetable or the mineral oil, and with adjuvant drug and the composite a kind of oils and fats suspending carrier of excipient.This method is very complicated, and needs a metal or the compound growth hormone of transition metal.For example, under the condition of strictness, in growth hormone solution, add zinc chloride and make zinc one growth hormone complex, but will through a plurality of steps centrifugal from the suspension that contains this complex the excessive zinc chloride of flush away.The solution that finally obtains then need carry out lyophilizing, and all processes that refines processing i.e. unusual tedium, when useless again.
The European patent open source literature has also been described a kind of containing for 216, No. 485 and has been suspended in such as the zinc in the oils and fats of Oleum Arachidis hypogaeae semen one growth hormonal composition.8mg said composition and 40mg growth hormone only show the 9 days drug effects in short ground exemplarily to the pig administration.In addition, this preparation method also with United States Patent (USP) 4,985, No. 404 are equally complicated.
United States Patent (USP) 4,863 discloses the method that a kind of preparation contains the implantable pill of growth hormone granule No. 736, this pill have as, Lac, Cera Flava and cellulosic polymer moieties barrier coatings.The release in vivo of this pill control growing hormone.Equally, the European patent open source literature also provides a kind of method for preparing the implantable medicament that contains growth hormone in penetration equipment for 374, No. 120.The European patent open source literature has also disclosed a kind of synthetic method that contains the implantable medicament of polypeptide and fatty acid for preparing for 246, No. 540.
In addition, United States Patent (USP) 4,786 has been put down in writing a kind of method for preparing implantable pill agent prescription No. 501, and this method comprises the mixed growth hormone, sucrose and ethyl cellulose, and apply this mixture with porous and atresia polyethylene.United States Patent (USP) 4,761 has also been discussed a kind of method for preparing implantable prescription No. 289, and it comprises mixed growth hormone and non-water-soluble polymer, adds a kind of non-water-soluble solvent and drying.Though these implantable prescriptions have the effect that keeps curative effect, they need underwent operative or special apparatus could implant or administration; Therefore, need relative complex and treatment sequence not too easily.
In addition, the European patent open source literature discloses a kind of compositions 193, No. 917, and it contains water dispersible and water miscible carbohydrate polymer, and a kind of tool biological activity growth hormone macromole.The European patent open source literature further discloses a kind of compositions that is dispersed in the peptide species in the oils and fats that contains for 314, No. 421, and its adopts a kind of carbohydrate polymer as dextran as support substance.The European patent open source literature also reported for 211, No. 691 and a kind ofly contained the compositions that is dispersed in the polypeptide in certain oils and fats with several Cera Flavas as support substance, but it has with the same shortcoming of above-mentioned those European patent open source literatures 193,917.In these compositionss, animal body usually is considered as antigen with carbohydrate polymers such as dextrans and induces reaction, and very sensitive, therefore is not suitable for life-time service.
A kind of compositions that is dispersed in the tocopherol and is furnished with the animal growth hormone of delay release action that contains has been described for Korean patent publication 91-15302 number.Because its high viscosity, this compositions are difficult to be used by injection, and have long tendency of holdup time in the administration tissue, can cause damage that tissue.
Therefore, the object of the present invention is to provide the method for a kind of somatotropin composition of preparation, said composition is long half time in living animal, does not have the effect of paying.
Another object of the present invention is to provide the somatotropin composition of a kind of the present invention's of employing method preparation.
According to the present invention, will provide a kind of method for preparing somatotropin composition, its release in vivo is that the time is controlled, this method comprises the steps: lecithin and growth hormone are dissolved in the aqueous solution, forms a kind of liposome growth hormone solution; The described liposome growth hormone solution of freezing drying under the conventional freezing drying condition; The liposome growth hormone that the described freezing drying that suspends in Tocopheryl derivatives is crossed is to make new compositions of the present invention.
Brief Description Of Drawings
The present invention is also by further being understood with reference to the following drawings, wherein:
Fig. 1 and Fig. 2 illustrate after injecting the present invention's compositions to milch cow, to the influence of milk crop;
Fig. 3 represents after the present invention's new compositions is injected pig to trophophase, the concentration of pig growth hormone in its serum;
After compositions with the present invention shown in Figure 4 is injected pig to trophophase, the concentration of blood urea nitrogen in its serum;
After Fig. 5 illustrates the present invention's compositions is injected pig to trophophase, the concentration of IGF-in its serum.
According to of the present invention, growth hormone solution mixes in homogenizer with lecithin, adopts then conventional method, and it is suspended in the composition that obtains the present invention in the Tocopheryl derivatives. Permitted eurypalynous growth hormone and can both be used for the present invention, as long as they possess desirable biologically active. This typical growth hormone comprises: BGH, pig growth hormone, sheep growth hormone etc. Although requiring, the present invention adopts metal one, or transition metal-composite growth hormone or with the growth hormone of the modified of low hydrogenation, the growth hormone of these kinds also can use. The growth hormone that can adopt also comprises the growth hormone that those make from the chief cell such as the contracting such as Escherichia coli and yeast through recombinant DNA technology, and the spontaneous growth hormone that extracts from the heavy body of the animal body brains such as ox, sheep and pig.
Can be used for Tocopheryl derivatives of the present invention and comprise the d1-alpha-tocopherol, d1-α-tocopherol acetate, d1-α-butanedioic acid tocopherol, d1-alpha-phosphate tocopherol, the 1-alpha-tocopherol, 1-α-tocopherol acetate, 1-α-butanedioic acid tocopherol, 1-alpha-phosphate tocopherol, and β, ξ1，ξ
2, a fertility amphyl; α-tocopherol acetate preferably. Tocopheryl derivatives is kept the normal reproduction such as animals such as rat, mouse, cavy, pig and oxen; Help prevent the animal muscle developmental defect; In vivo the slowly-releasing of growth hormone plays the effect of carrier. In addition, Tocopheryl derivatives prevents irregular muscular movement in vivo, perhaps strengthens the intensity of muscle. Tocopherol can also prevent the irregular muscular movement of chicken, or makes the muscle hardening, also can prevent the pimelitis of mink, pig or cat. The amount of the tocopherol that adopts in the present composition is to account for 85～99% of said composition weight, preferred 90～99%.
The bioactive growth hormone that has that the present invention adopts mixes with lecithin, its mixing ratio be 7: 3 to 8: the 2(weight ratio). If the amount of growth hormone is less than lower bound (i.e. 70% weight), it is difficult to demonstrate biologically active. If the amount of growth hormone surpasses its upper limit (i.e. 80% weight), then be difficult to form liposome growth hormone mixture.
Be present in the lecithin control growing hormone release time in animal body in the present composition.Typically being suitable for lecithin of the present invention comprises: phosphatidylcholine, lysophosphatide (Lysophospholipid), plasmalogen and sphingomyelins.
In addition, can add suitable excipient and/or adjuvant drug so that the present composition can be made various types of dosage forms.
As mentioned above, in some known compositions, growth hormone need be with metal or transition metal, and the technology by complexity comprises that dialysis forms composite form, because in vivo its dissolubility must be lower, purpose is to obtain slow release effect.Growth hormone also can overdosage, to cause the impact effect of beginning.
On the contrary, compositions by the present invention's preparation, comprise a kind of liposome growth hormone that is suspended in the freezing mistake in the tocopherol carrier, when it during to the animal body administration, needn't adopt the program of the sort of complexity, mode that promptly can slow release discharges the biologically active growth hormone, it is very simple and economical to refine processing whole recipe ingredient and treatment sequence, the more important thing is that the prescription of the present composition demonstrates growth hormone in vivo and is accompanied by lower initial release or impacts a kind of high-quality release type that discharges suddenly.
Metal in the prescription of the metal composite growth hormone of available technology adopting or transition metal can cause to make us so paying of considering acts on, and the present composition does not have the effect of paying.The used Tocopheryl derivatives of the present invention has certain pharmacology assosting effect in live body, and has and alleviate or prevent the repulsive interaction of live body to the present composition.
Further explain the present invention below with reference to embodiment, these embodiment do not have the intention of the restriction scope of the invention.
Embodiment 1
Getting (the bovine growth hormone solution 30.03mg/l that produces with recombinant DNA technology (Lucky Limited)) bovine growth hormone solution 300ml, with the L-α that extracts in the Semen sojae atricolor-phosphatidylcholine IV-S(L-α-lecithin) 3g mixed in homogenizer 20 minutes.This solution was poured into a flask through a microfluidization instrument (microfluidizer) under 5 minutes, 4 ℃, quick freezing is to bearing 70 ℃, freezing then drying under dry ice-propanone is bathed.To contain powder 133.3mg after the freezing drying of L-α-phosphatidylcholine and bovine growth hormone in homogenizer with the α one tocopherol uniform mixing of 1ml 10 minutes.
Select for use 10 just to do experiment for Hao Sidun (Holstein) milch cow in suckling mid-term.Every per two weeks of cattle are injected compositions of the present invention totally 6 times.Wherein 5 cattle are experimental group, and 5 cattle are not injected said composition as matched group in addition.Shoulder first top subcutaneous injection said composition.After the injection, every day measure milk output, average every day, milk yield saw Table 1 and Fig. 1.
Method by embodiment 1 prepares the present composition, and the bovine growth hormone of just getting after the freezing drying of 333.5mg is mixed with the α-tocopherol acetate of 37.02mg lecithin with 1ml.
Select the Hao Sidun milch cow in 12 suckling mid-terms to experimentize.Every totally 6 times of injecting this compound composition of 2ml per two weeks of cattle.Wherein 6 cattle are as experimental group, and 6 cattle are matched group in addition.Experimentize by the identical method described in the embodiment 1, its experiment the results are shown in Table 2 and Fig. 2.
Table 1 present composition is to the effect of milk production every day
Unit (kg)
Matched group injection group
Inject preceding 21.50 23.91
The master penetrates 21.66 27.75 for the first time
For the second time inject 21.84 28.18
Inject 21.51 28.10 for the third time
The 4th injection 20.76 27.73
The 5th injection 19.59 28.06
The 6th injection 18.51 27.17
The 6th injection 17.94 23.45
After two weeks
Table 2 present composition is to the effect of milk production every day
Unit (kg)
Matched group injection group
Inject preceding 26.14 25.50
For the first time inject 22.6 23.8
For the second time inject 23.8 25.6
Inject 22.3 24.8 for the third time
The 4th injection 22.0 24.5
The 5th injection 20.7 23.0
The 6th injection 21.0 23.2
The 6th injection back 18.9 19.3
Two weeks
Prepare the pig growth hormone compositions by embodiment 1 identical method.Select 14 hog, every nose heave about 60kg does experiment.Wherein every pigs are injected compound composition 1.5ml of the present invention per three weeks of 7 pigs, and totally twice, 7 pigs are used as matched group and do not inject said composition in addition.Injection back three their body weight of all weighings and foodstuff consumptions.Calculate frequency of administration (FE, feed efficiency kg/day).Increment number (ADG, average daily gain kg/day) and the frequency of administration (the FE=amount of eating/weight increase amount) of average every day shown in the table 3.
Table 3 average every day of increment and frequency of administration
Matched group injection group
First three all ADG 0.94 0.97
FE 3.55 3.33 afterwards
Second three all ADG 0.81 0.96
FE 4.28 3.31 afterwards
Embodiment 4
Prepare the pig growth hormone compound composition by embodiment 1 identical method.Experimentize every heavily about 60kg of pig with 6 hog.Every said composition of injecting 1.5ml of 3 pigs wherein.Other 3 pigs not injectable composition are cooked matched group.Measure serum pig growth hormone concentration (PST), serum urea nitrogen (BUN) concentration and IGF-concentration.
It records and the results are shown in Table 4, Fig. 4 and Fig. 5
Table 4 blood-serum P ST concentration, the concentration of BUN and IGF-
Blood-serum P ST IGF-I BUN blood-serum P ST IGF-I BUN
My god (ng/ml) (ng/ml) (mg/dl) (ng/ml) (ng/ml) (mg/dl)
0 1.43 343 14.5 1.44 441 15.0
1 1.52 306 15.7 325 891 4.5
3 1.15 308 17.4 46.9 1135 8.0
6 1.42 356 15.0 8.30 1018 6.0
10 1.44 351 19.8 3.10 692 16.5
14 1.46 354 19.7 1.02 506 19.0
21 1.80 348 23.3 1.10 438 17.7
As above show finding, the compositions for preparing by method of the present invention has the long half-life when supplying medicine to animal, and has no side effect, because its viscosity is hanged down the suitable injection of using, and is fit to use continuously.The very easy administration of said composition needn't be with performing the operation or special apparatus.In addition, its method for making is very simple and economical.
Can make amendment and change it about the description of the invention described above particular embodiment should be regarded as common existing these personnel in this area, limit within the protection domain but also fall into claim of the present invention.
Claims (10)
1, preparation contains the method for the slow releasing composition of growth hormone, and it comprises the steps:
Growth hormone is made a mixture with the lecithin uniform mixing;
This mixture is dissolved in formation liposome growth hormone solution in the aqueous solution;
Under the conventional freezing condition, the described liposome growth hormone solution of freezing drying; And the described liposome growth hormone after freezing that suspends in Tocopheryl derivatives is made slow releasing composition.
2, the method for claim 1, wherein said growth hormone is selected from bovine growth hormone, pig growth hormone and sheep growth hormone.
3, the method for claim 1, wherein said growth hormone prepares through recombinant DNA technology.
4, the method for claim 1, wherein said tocopherol is selected from the dl-alpha-tocopherol, dl-α-tocopherol acetate, dl-α-succinic acid tocopherol, dl-alpha-phosphate tocopherol, the 1-alpha-tocopherol, 1-α-tocopherol acetate, 1-α-succinic acid tocopherol, 1-alpha-phosphate tocopherol, and β, ξ
1, ξ
2,-Tocopheryl derivatives.
5, method as claimed in claim 4, wherein said Tocopheryl derivatives are dl-α-tocopherol acetates.
6, the method for claim 1, wherein said lecithin is selected from phosphatidylcholine, lysophosphatide (Lysophospholipid), plasmalogen and sphingomyelins.
7, the method for claim 1, the weight mixing ratio of wherein said growth hormone and lecithin is 7: 3 to 8: 2.
8, the method for claim 1, the amount of the liposome growth hormone after the wherein said freezing drying counts 1% to 15% by composition total weight, and the amount of Tocopheryl derivatives is 85% to 99%.
9, a kind of growth hormone slow releasing composition by the described method preparation of claim 1.
10, compositions as claimed in claim 9 also contains excipient and/or adjuvant drug.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR9222551 | 1992-11-27 | ||
| KR1019920022551A KR940011013A (en) | 1992-11-27 | 1992-11-27 | Method for preparing sustained release somatropin formulation |
| KR22551/92 | 1992-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1087277A true CN1087277A (en) | 1994-06-01 |
| CN1103601C CN1103601C (en) | 2003-03-26 |
Family
ID=19344061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93101680A Expired - Lifetime CN1103601C (en) | 1992-11-27 | 1993-02-24 | Release-controlled somatotropin composition and method for prepartion thereof |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR940011013A (en) |
| CN (1) | CN1103601C (en) |
| CZ (1) | CZ280429B6 (en) |
| MY (1) | MY134714A (en) |
| SK (1) | SK279352B6 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100365678B1 (en) * | 2000-03-24 | 2002-12-26 | 주식회사 엘지생명과학 | The somatotropin formulation of improved syringeability |
| KR100423895B1 (en) * | 2001-02-19 | 2004-03-24 | 주식회사 엘지생명과학 | Compositions of suspensions of ceftiofur hydrochloride |
| CN103751769B (en) * | 2013-12-25 | 2015-08-19 | 楼秀余 | A kind of lyophilizing recombinant human somatropin capsule and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| AU7128887A (en) * | 1986-02-10 | 1987-08-25 | Liposome Technology, Inc. | Controlled-release liposome delivery system |
| JP2817883B2 (en) * | 1987-12-04 | 1998-10-30 | ザ リポソーム カンパニー，インコーポレイテッド | Highly complete liposomes and their formulations and uses |
-
1992
- 1992-11-27 KR KR1019920022551A patent/KR940011013A/en not_active Application Discontinuation
-
1993
- 1993-02-06 MY MYPI93000193A patent/MY134714A/en unknown
- 1993-02-24 CN CN93101680A patent/CN1103601C/en not_active Expired - Lifetime
- 1993-11-26 CZ CZ932552A patent/CZ280429B6/en not_active IP Right Cessation
- 1993-11-26 SK SK1328-93A patent/SK279352B6/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SK132893A3 (en) | 1994-07-06 |
| CZ280429B6 (en) | 1996-01-17 |
| MY134714A (en) | 2007-12-31 |
| SK279352B6 (en) | 1998-10-07 |
| KR940011013A (en) | 1994-06-20 |
| CN1103601C (en) | 2003-03-26 |
| CZ255293A3 (en) | 1994-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1165294C (en) | Controlled release preparations having multi-layer structure | |
| CN1107497C (en) | Controlled-release pharmaceutical preparation | |
| KR100245395B1 (en) | Formulations and methods for providing prolonged local anesthesia | |
| CN1026463C (en) | Chewable capsules | |
| JP3313113B2 (en) | Biocompatible implants for controlling ovulation in mares | |
| KR930008954B1 (en) | Controlled release bases for pharmaceuticals | |
| US5219572A (en) | Controlled release delivery device for macromolecular proteins | |
| JP2003517014A (en) | Pharmaceutical implant containing immediate release and sustained release components and administration method | |
| TWI405578B (en) | Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits | |
| EP0702959A1 (en) | Cross-linked gelatin gel preparation containing basic fibroblast growth factor | |
| CN101400363A (en) | Pharmaceutical compositions with enhanced stability | |
| CN1120458A (en) | Physiologically active peptide compositions | |
| EP0463061A1 (en) | Controlled release delivery device for macromolecular proteins. | |
| JP2004535473A5 (en) | ||
| ZA200700068B (en) | Sustained release composition | |
| US6245346B1 (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
| CN1056746C (en) | Lyophilisierte, wirkstoffhaltige emulsion | |
| CN1145496C (en) | Novel formulation for peptide release | |
| CN1087277A (en) | Contain slow releasing composition of growth hormone and preparation method thereof | |
| CN1228708A (en) | Peptide-containing drug compositions for oral administration | |
| EP0873134B1 (en) | Aqueous prolonged release formulation comprising bovine growth hormone-releasing factor | |
| CN1170523C (en) | Sustained-release drug formulations for implantation | |
| WO1996010395A1 (en) | Controlled-release pharmaceutical preparations | |
| WO2003011214A2 (en) | Novel methods and formulations for administration of active agents | |
| US5891456A (en) | Glyceryl monosterate based biodegradable implants for site-specific delivery of drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20130224 Granted publication date: 20030326 |